Results 31 to 40 of about 12,220,634 (288)

Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels [PDF]

, 2007
Disrupted-in-schizophrenia 1 (DISC1) is a genetic susceptibility factor for schizophrenia and related severe psychiatric conditions. DISC1 is a multifunctional scaffold protein that is able to interact with several proteins, including the independently ...
Millar, J.K., Mackie, S., Houslay, M. D., Porteous, D.J., Hill, E. V., Hill, E.V., Porteous, D. J., Bolger, G.B., Murdoch, H., Klussmann, E., Collins, D. M., Millar, J. K., Bolger, G. B., Houslay, M.D., Collins, D.M.   +14 more
core   +1 more source

Phosphodiesterase 5 inhibitors for pulmonary hypertension [PDF]

Cochrane Database of Systematic Reviews, 2017
Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right-heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left-heart disease (PH-LHD ...
Hayley, Barnes, Zoe, Brown, Andrew, Burns, Trevor, Williams   +3 more
openaire   +3 more sources

A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool

Journal of Research in Pharmacy Practice, 2015
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are ...
Nahid Eskandari, Omid Mirmosayyeb, Gazaleh Bordbari, Reza Bastan, Zahra Yousefi, Alireza Andalib   +5 more
doaj   +1 more source

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study

Pulmonary Circulation, 2020
Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson, Oisin Butler, Roger Hesselstrand, Katsiaryna Holl, Kjell Jansson, Rogier Klok, Göran Rådegran, Stefan Söderberg, Barbro Kjellström   +8 more
doaj   +1 more source

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review

Journal of Ophthalmic & Vision Research, 2021
Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso, João Crispim Ribeiro, Eduardo P. Miranda   +2 more
doaj   +1 more source

Phenanthrenes from as Novel Phosphodiesterase-5 Inhibitors

Natural Product Communications, 2017
Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon ...
Prapapan Temkitthawon, Kanokwan Changwichit, Nantaka Khorana, Jarupa Viyoch, Khanit Suwanborirux, Kornkanok Ingkaninan   +5 more
doaj   +1 more source

Effect of phosphodiesterase-5 inhibitor on hearing

The Journal of Laryngology & Otology, 2009
AbstractObjective:Following a report of sudden hearing loss in a patient taking phosphodiesterase type 5 inhibitor, and a Food and Drug Administration announcement concerning this class of drugs, a study was planned to investigate if ototoxicity occurs in patients using phosphodiesterase 5 inhibitor for erectile dysfunction.Methods:Eighteen patients ...
Okuyucu, S., Guven, O. E., Akoglu, E., Ucar, E., Dagli, S.   +4 more
openaire   +2 more sources

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss [PDF]

, 2013
Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been increasingly used today and some of the users have developed sudden sensorineural hearing loss.ObjectiveTo present two patients with sudden deafness developed ...
Bahmad Jr,Fayez, Bahmad Júnior, Fayez, Barreto, Monique Antunes de Souza Chelminski, Bahmad, Fayez, Monique Antunes de Souza Chelminski Barreto, Barreto,Monique Antunes de Souza Chelminski, Fayez Bahmad Jr   +6 more
core   +1 more source

Phosphodiesterase 5 inhibitors: are they cardioprotective? [PDF]

Cardiovascular Research, 2009
A growing body of animal studies provides evidence for potential cardioprotective effects of inhibitors of the enzyme phosphodiesterase isoform 5. Infarct size reduction by administration of phosphodiesterase 5 inhibitors was described in various experimental models of ischaemia and reperfusion.
Thorsten, Reffelmann, Robert A, Kloner
openaire   +2 more sources

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy

, 2010
Mitchell S Buckley1, Robin L Staib1, Laura M Wicks1, Jeremy P Feldman21Department of Pharmacy, Banner Good Samaritan Medical Center, and 2Arizona Pulmonary Specialists Ltd, Phoenix, Arizona, USAAbstract: Pulmonary arterial hypertension (PAH) is a ...
null Robin Staib, Mitchell S Buckley, Jeremy Jeremy Feldman, null Laura Wicks, et al, null Mitchell Buckley, Robin L Staib, Laura M Wicks   +7 more
core   +1 more source